Progress in the development of a therapeutic vaccine for breast cancer

Breast Cancer: Targets and Therapy

Volumn 2, Issue , 2010, Pages 25-36

  Coveler, Andrew L ^a   Bates, Nicole E ^a   Disis, Mary L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Breast; Cancer; HER 2 neu; hTERT; MUC 1; Vaccine

Indexed keywords

BIOVAXID; CANCER VACCINE; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; DNA VACCINE; E 75; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2 VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MUCIN 1; MUCIN 1 VACCINE; PEPTIDE VACCINE; PROVENGE; RECOMBINANT INTERLEUKIN 2; TELOMERASE REVERSE TRANSCRIPTASE; TELOMERASE REVERSE TRANSCRIPTASE PEPTIDE VACCINE; TRASTUZUMAB; TUMOR ANTIGEN; TUMOR CELL VACCINE; UNCLASSIFIED DRUG;

ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG DESIGN; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HELPER CELL; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSTIMULATION; MELANOMA; SIDE EFFECT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 77954545690     PISSN: None     EISSN: 11791314     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Coley WB. The treatment of malignant tumors by repeated inoculations of Erysipelas: With a report of ten original cases. Am J Med Sci. 1893;105(5):487.
2. Goedegebuure PS, Watson MA, Viehl CT, Fleming TP. Mammaglobinbased strategies for treatment of breast cancer. Curr Cancer Drug Targets. 2004;4(6):531-542.
3. Burnet FM. Immunological aspects of malignant disease. Lancet. 1967;1(7501):1171-1174.
4. Shankaran V, Ikeda H, Bruce AT, et al. IFN gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410(6832):1107-1111. 10.1038/35074122.
5. Anderson KS. Tumor vaccines for breast cancer. Cancer Invest. 2009;27(4):361-368. 10.1080/07357900802574421.
6. Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase III trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009; 115(16): 3670-3679. 10.1002/cncr.24429.
7. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006;24(19):3089-3094. 10.1200/JCO.2005.04.5252.
8. Schellhammer PF, Higano CS, Berger ER, et al. A randomized, double-blind, placebo-controlled, multi-center, phase III trial of sipuleucel-T in men with metastatic, androgen independent prostatic adenocarcinoma (AIPC). American Urological Association, Annual Meeting. 2009.
9. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258-1265. 10.1182/ blood-2003-12-4434.
10. Schuster SJ, Neelapu SS, Gause BL, et al. Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: phase III clinical trial results. [Meeting Abstracts] J Clin Oncol. 2009;27 Suppl 18:2.
11. Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg. 1998;228(3):307-319.
12. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 1998;4(3):321-327.
13. Schwartzentruber DJ, Lawson D, Richards J, et al. A phase III multiinstitutional randomized study of immunization with the gp100: 209-217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma. J Clin Oncol. 2009;27 Suppl 18.
14. Emens LA, Asquith JM, Leatherman JM, et al. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation [Breast Cancer]. Journal of Clinical Oncology. 2009;27(35):5911-5918. http://jco.ascopubs.org. 10.1200/JCO.2009.23.3494
15. Disis ML, Shiota FM, Cheever MA. Human HER-2/neu protein immunization circumvents tolerance to rat neu: a vaccine strategy for 'self' tumour antigens. Immunology. 1998;93(2):192-199.
16. Cheever MA, Allison JP, Ferris AS, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15(17):5323-5337.
17. Bargmann CI, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature. 1986; 319(6050):226-230. 10.1038/319226a0.
18. Coussens L, Yang-Feng TL, Liao YC, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 1985;230(4730):1132-1139.
19. Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene. 1990;5(7):953-962.
20. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/ neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707-712.
21. Disis ML, Cheever MA. HER-2/neu protein: a target for antigenspecific immunotherapy of human cancer. Adv Cancer Res. 1997;71:343-371.
22. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20(3):719-726.
23. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-1684. 10.1056/NEJMoa052122.
24. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659-1672. 10.1056/NEJMoa052306.
25. Gendler SJ, Cohen EP, Craston A, Duhig T, Johnstone G, Barnes D. The locus of the polymorphic epithelial mucin (PEM) tumour antigen on chromosome 1q21 shows a high frequency of alteration in primary human breast tumours. Int J Cancer. 1990;45(3):431-435.
26. Patton S, Gendler SJ, Spicer AP. The epithelial mucin, MUC1, of milk, mammary gland and other tissues. Biochim Biophys Acta. 1995;1241(3):407-423.
27. van der Vegt B, de Roos MA, Peterse JL, et al. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma. Histopathology. 2007;51(3): 322-335. 10.1111/j.1365-2559.2007.02757.x.
28. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T Cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203-213. 10.1056/NEJMoa020177.
29. von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P, et al. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol. 2000;18(3):574-583.
30. Liu J, Chen W, Schwarer AP, Li H. Telomerase in cancer immunotherapy. Biochimica et Biophysica Acta (BBA) Reviews on Cancer. [In Press] DOI: 10.1016/j.bbcan.2009.09.001.
31. Kim N, Piatyszek M, Prowse K, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266(5193):2011-2015.
32. Domchek SM, Recio A, Mick R, et al. Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance. Cancer Res. 2007;67(21):10546-10555. 10.1158/0008-5472. CAN-07-2765.
33. Peoples GE, Gurney JM, Hueman MT, et al. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol. 2005;23(30):7536-7545. 10.1200/ JCO.2005.03.047.
34. Peoples GE, Holmes JP, Hueman MT, et al. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military cancer institute clinical trials group study I-01 and I-02. Clin Cancer Res. 2008;14(3):797-803. 10.1158/1078-0432.CCR-07-1448.
35. Benavides LC, Gates JD, Carmichael MG, et al. The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military cancer institute clinical trials group study I-01 and I-02. Clin Cancer Res. 2009;15(8):2895-2904. 10.1158/1078-0432. CCR-08-1126.
36. Nahta R, Yu D, Hung M, Hortobagyi GN, Esteva FJ. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. 2006;3(5):280. http://dx.doi.org/10.1038/ ncponc0509
37. Koski GK, Cohen PA, Roses RE, Xu S, Czerniecki BJ. Reengineering dendritic cell-based anti-cancer vaccines. Immunol Rev. 2008;222: 256-276. 10.1111/j.1600-065X.2008.00617.x.
38. Czerniecki BJ, Koski GK, Koldovsky U, et al. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res. 2007;67(4):1842-1852. 10.1158/0008-5472.CAN-06-4038.
39. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92(3):205-216. 10.1093/jnci/92.3.205.
40. Knutson KL, Schiffman K, Cheever MA, Disis ML. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin Cancer Res. 2002;8(5):1014-1018.
41. Disis ML, Gooley TA, Rinn K, et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol. 2002;20(11):2624-2632.
42. Disis ML, Cheever MA. HER-2/neu oncogenic protein: issues in vaccine development. Crit Rev Immunol. 1998;18(1-2):37-45.
43. Salazar LG, Coveler AL, Swensen RE, et al. Kinetics of t umor-s pecific T-cell response development after active immunization in patients with HER-2/neu overexpressing cancers. Clin Immunol. 2007;125(3):275-280. 10.1016/j.clim.2007.08.006.
44. Disis ML, Grabstein KH, Sleath PR, Cheever MA. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res. 1999;5(6):1289-1297.
45. Salazar LG, Goodell V, O'Meara M, et al. Persistent immunity and survival after immunization with a HER2/neu (HER2) vaccine. J Clin Oncol (Meeting Abstracts). 2009;27(15S):3010.
46. Disis ML, Wallace DR, Gooley TA, et al. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol. 2009:27(28) 10.1200/JCO.2008.20.6789.
47. Coveler AL, Goodell V, Webster DJ, et al. Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced T cell immunity. Breast Cancer Res Treat. 2009;113(1):95-100. 10.1007/s10549-008-9910-y.
48. Goydos JS, Elder E, Whiteside TL, Finn OJ, Lotze MT. A phase I trial of a synthetic mucin peptide vaccine: induction of specific immune reactivity in patients with adenocarcinoma. J Surg Res. 1996;63(1):298-304. DOI: 10.1006/jsre.1996.0264.
49. Reddish MA, MacLean GD, Koganty RR, et al. Anti-MUC-1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC-1 peptide. Int J Cancer 1998;76(6):817-823. http:// dx.doi.org/10.1002/(SICI)1097-0215(19980610)76:6,817::AIDIJC9.3.0.CO;2-0. 10.1002/(SICI)1097-0215(19980610)76:6,817::AID-IJC9.3.0.CO;2-0
50. Disis ML, Knutson KL, McNeel DG, Davis D, Schiffman K. Clinical translation of peptide-based vaccine trials: the HER-2/neu model. Crit Rev Immunol. 2001;21(1-3):263-273.
51. Disis ML, Schiffman K, Guthrie K, et al. Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein - based vaccine. J Clin Oncol. 2004;22(10):1916-1925. 10.1200/JCO.2004.09.005.
52. Apostolopoulos V, Pietersz GA, Tsibanis A, et al. Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC-1 [ISRCTN71711835]. Breast Cancer Res. 2006;8(3):R27. 10.1186/bcr1505.
53. Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood. 2000;96(9): 3102-3108.
54. Pecher G, Haring A, Kaiser L, Thiel E. Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial. Cancer Immunol Immunother. 2002;51(11-12):669-673. 10.1007/s00262-002-0317-z.
55. Vonderheide RH, Domchek SM, Schultze JL, et al. Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res. 2004;10(3):828-839.
56. Salazar LG, Slota M, Wallace D, et al. A phase I study of a DNA plasmid based vaccine encoding the HER2/neu (HER2) intracellular domain (ICD) in subjects with HER2+ breast cancer. J Clin Oncol (Meeting Abstracts). 2009;27 Suppl 15:3054.
57. Salazar LG, Coveler A, Fintak PA, et al. Low dose of a plasmid DNA vaccine encoding the HER-2/neu (HER2) intracellular domain (ICD) effectively stimulate tumor specific immunity. San Antonio Breast Cancer Symposium. 2006;100 Suppl 1.
58. Gulley JL, Arlen PM, Tsang KY, et al. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res. 2008;14(10):3060-3069. 10.1158/1078-0432.CCR-08-0126.
59. Collins R Jr, Shpilberg O, Drobyski W, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15(2):433-444. http://jco.ascopubs. org/cgi/content/abstract/15/2/433
60. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-390. 10.1056/ NEJMoa0708857.
61. Vidal L, Gafter-Gvili A, Leibovici L, et al. Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: Systematic Review and Meta-analysis of Randomized Trials. J Natl Cancer Inst. 2009;101(4):248-255. 10.1093/jnci/djn478; http://jnci.oxfordjournals.org/cgi/content/abstract/jnci;101/4/248
62. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. N Engl J Med. 2001;344(11):783-792. 10.1056/ NEJM200103153441101.
63. Czerniecki BJ, Roses RE, Koski GK. Development of vaccines for high-risk ductal carcinoma in situ of the breast. Cancer Res. 2007. 67(14):6531-6534. 10.1158/0008-5472.CAN-07-0878.